Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...
Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...
Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...
41mon MSN
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...
The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...
The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...
The World Health Organization raises alarms over increased West Bank violence affecting healthcare. In Congo, over 50 die due ...
Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...
Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.
Medicenna Therapeutics (MDNA) announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in ...
The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results